Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy

  • Batool, Razia
  • Soler, María
  • Colavita, Francesca
  • Fabeni, Lavinia
  • Matusali, Giulia
  • Lechuga, Laura M.
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 102 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC50) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer., Financial support is acknowledged from the SensCELL project (Ref. No. PGC-2018-099870), funded by the Spanish Ministry of Science and Innovation (MCIN), the Spanish Research Agency (AEI), and the European Regional Development Fund (ERDF), and from the CONVAT project (Ref. 101003544), funded by the H2020 Research and Innovation Programme of the European Commission (H2020-SC1-PHE-Coronavirus-2020). RB acknowledges the economic support (Ref. PRE2019- 089357) from MCIN and AEI linked to the project SEV-2017-0706-19-4. MS acknowledges the economic support of the Ramon y Cajal Grant (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. INMI also acknowledges funding from the European Virus Archive – GLOBAL (Grant No. 871029). The ICN2 is supported by the CERCA programme (Generalitat de Catalunya) and the Severo Ochoa Centres of Excellence programme, funded by the AEI (Grant. No. SEV-2017-0706)., Peer reviewed